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Coccidioidomycosis, a systemic disease
caused by the dimorphic fungus Coccidioides
immitis,  is endemic in the southwestern United
States and parts of Mexico and in Central and
South America (1,2). The incidence of this
systemic mycosis in disease-endemic areas
increased during the 1990s (3-5). An estimated
100,000 infections occur in the United States
annually, and 1 in 200 infections progresses to
disseminated disease (1,6). Sporadic cases of
coccidioidomycosis have been reported among
visitors to the Southwest, and one earlier report
recognized coccidioidomycosis as a serious travel
hazard for visitors to that region (7-9).
C. immitis, a soil fungus, inhabits a unique
ecologic niche in the topsoil of the lower Sonoran
life zone (10). The infectious propagules are
arthroconidia, single-cell fragments of mycelial
threads, which become easily airborne to cause
inhalation exposure. In the alveoli, arthroconidia
undergo dimorphic transition to spherules,
which fragment into endospores. When released
from the spherule, each endospore can act as a
new infectious unit in vivo (1). C. immitis, one of
the most virulent and infectious fungal
pathogens, poses a serious occupational hazard
for laboratory personnel, especially in areas
where the disease is not endemic and workers
are less likely to practice biohazard safety level
(BSL)-3 containment, which is required for the
handling of this pathogen. The serious biohazard
potential of C. immitis has led to its inclusion
among the biological agents covered under the
recently enacted Anti-Terrorist and Effective
Death Penalty Act, which regulates interstate
transport of infectious materials (11).
The extent and source of C. immitis
infections have not been thoroughly investigated
in areas where the disease is not endemic. In this
study we summarize discharge data from
persons with coccidioidomycosis hospitalized in
New York, a nondisease-endemic area with a
single coccidioidomycosis case report (7). In
addition, we tested a proposed set of molecular
markers for multilocus genotyping of C. immitis
to determine the geographic origins of fungal
isolates obtained in this study.
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Coccidioidomycosis, a systemic fungal disease caused by Coccidioides immitis, is
endemic in the southwestern United States and in parts of Mexico and Central and
South America. Only sporadic cases have been reported in areas (including New York)
where the disease is not endemic. We used hospital discharge records and state
mycology laboratory data to investigate the characteristics of C. immitis infections
among New York State residents. From 1992 to 1997, 161 persons had hospital
discharge diagnoses of coccidioidomycosis (ICD9 Code 114.0 - 114.5, 114.9). From
1989 to 1997, 49 cultures from patients were confirmed as C. immitis; 26 of these
patients had traveled to disease-endemic areas. Fourteen of 16 isolates had multilocus
genotypes similar to those of Arizona isolates, which corroborates the travel-related
acquisition of the disease. Our results indicate that coccidioidomycosis may be more
common in New York residents than previously recognized. Increased awareness
among health-care providers should improve timely diagnosis of coccidioidomycosis
and prevention of associated illnesses and deaths among patients in nondisease-
endemic areas.26 26 26 26 26 Emerging Infectious Diseases Vol. 6, No. 1, January–February 2000
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The Study
Data on hospitalization for coccidioidomyco-
sis in the state of New York from 1992 to 1997
were obtained from the New York Statewide
Planning and Research Cooperative System,
which compiles uniform inpatient data from all
general acute-care hospitals (all public and
private hospitals and hospital-based and free-
standing ambulatory surgery facilities).
Patients were selected if their hospitaliza-
tions listed a primary or secondary discharge
diagnosis of coccidioidomycosis (ICD9 114.0-
114.5, 114.9) during 1992 to 1997. Information
was collected from hospital discharge data
abstracts and uniform billing forms for age at
admission, sex, race, ethnicity, county of
residence, insurance status, seasonality, disposi-
tion of patient, hospital length of stay, and total
hospital cost.
Hospital medical records were requested
from the 16 patients with positive C. immitis
cultures available for multilocus genotyping
(1994-1997). These records were reviewed for
travel histories.
Laboratory Methods
All suspect C. immitis isolates were
transported and processed with full safety
precautions in a BSL-3 facility. The isolates were
subcultured on modified Sabouraud’s agar and
Mycosel agar, morphologic and microscopic
features were examined, and cultures were
processed for specific nucleic acid detection. The
AccuPROBE  C. immitis culture identification
test (Gen-Probe Inc., San Diego, CA) was used to
confirm the fungal identity. Before 1993, most
culture identifications were confirmed by using a
C. immitis exoantigen test kit (Scott Laborato-
ries Inc., Fiskeville, RI).
The fungal DNA was extracted from mycelial
cultures according to the method of Pan et al.
(12). PCR-RFLP was done as described by Burt
et al. (13), with minor modifications. We
studied five of the 10 loci originally used for each
C. immitis isolate because analysis showed these
loci to be most useful for strain differentiation
(13). The loci/restriction enzymes used included
a1/BsrI, bg/DdeI, bl/DdeI, bq/HinFI, and e1/
BsmI. Accordingly, California isolates were
expected to show polymorphism at e1, and Arizona
isolates could be either positive or negative at each
locus, while isolates from Texas would be
polymorphic only for the a1, bq, and e1 loci.
Findings
Hospital discharge data from 1992 to 1997 in
New York showed 181 hospitalizations with
coccidioidomycosis as the primary or secondary
discharge diagnoses (Table 1). The yearly
distribution of hospitalizations was 30 (1992), 28
(1993), 30 (1994), 33 (1995), and 32 (1996), with
no discernible seasonal pattern. Coccidioidomy-
cosis was the primary diagnosis in 75 hospitaliza-
tions and the secondary diagnosis in 106. The
clinical diagnoses according to ICD9 Codes
included 105 hospitalizations for pulmonary
coccidioidomycosis (114.0, 114.5), one with
extrapulmonary coccidioidomycosis (114.1), five
with coccidioidal meningitis (114.2), 18 with
other forms of coocidioidomycosis (114.3), 19
with chronic pulmonary coccidioidomycosis
(114.4), and 33 with unspecified coccidioidomyco-
sis (114.9). The mean length of stay was 16 days,
with an average hospital cost of $22,516.00.
One hundred sixty-one patients were
hospitalized, of whom five had two hospitaliza-
tions, two had three, one had four, and one had
nine (Table 1). Thirty-two (20%) patients had
HIV, 16 patients (10%) had cancer, and 18
patients (11%) died while hospitalized. Overall,
Table 1. Coccidioidomycosis hospital discharge data,
New York State, 1992–1997
Characteristic  N (%)
Total hospitalizations 181
Total patients 161
Male   93 (58)
Female   68 (42)
Race
White 128 (79)
Black   18 (11)
Asian/Pacific Islander     2 (  1)
Other     9 (  6)
Unknown     4 (  3)
Ethnicity
Hispanic     4 (  2)
Non-hispanic 151 (94)
Unknown     6 (  4)
Coccidioidomycosis diagnosis
Primary   75 (41)
Secondary 106 (59)
Concurrent diagnosis
HIV   32 (20)
Cancer   16 (10)
Died while in hospital   18 (11)
Mean length of stay (days)   16
Age range (yrs) 0-93  (median 58)
Mean hospital charge $22,516.0027 27 27 27 27 Vol. 6, No. 1, January–February 2000 Emerging Infectious Diseases
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120 (75%) of these 161 patients were either >54
years of age, had cancer, or were HIV infected.
Mean and median ages for HIV-infected
patients were 36 and 33 years, compared with 66
and 64 years for cancer patients and 59 and 63
years for others. Further comparison of HIV-
infected patients with patients who had neither
cancer nor HIV infection showed differences in
percentages with a primary diagnosis of
coccidioidomycosis (22% vs 50%), male sex (81%
vs 50%), black race (31% vs 5%), and death
during hospitalization (31% vs 6%).
Forty-nine C. immitis cultures were identi-
fied at the state mycology laboratory from 1989
to 1997 (Figure).
Sixteen patient isolates were available for
multilocus genotyping. The hospital records of
these patients were reviewed to determine the
likely source of infection. All had a history of
travel to the Southwest, with 12 of 16 patients
traveling to Arizona. However, date(s) of travel
could not be correlated with onset of the disease.
The typing of five alleles allowed unambiguous
matches with Arizona genotypes for eight
isolates from patients whose histories supported
this conclusion (Table 2). It was also possible to
type the respective C. immitis isolates to Arizona
in five instances in which patients gave a history
of travel to more than one disease-endemic area
(four with travel to Arizona). The Arizona
genotypes of three isolates (474-97, 639-97, and
779-97) did not match, as these patients had a
history of travel to California, California and
Mexico, and California, respectively.
Conclusions
Before 1994, the Centers for Disease Control
and Prevention (CDC) definition for coccidioido-
mycosis relied solely on a physician’s clinical
diagnosis (5). The current Council of State and
Territorial Epidemiologists/CDC surveillance
case definition requires the presence of both
clinically compatible symptoms and laboratory
evidence of infection (5). The laboratory criteria
include a positive culture, positive histopatho-
logic results, molecular evidence of C. immitis,  a
positive serologic test, or a positive skin test. The
retrospective nature of this study and our
Figure. Coccidioidomycosis in New York, 1989–1997. The figure on the left highlights coccidioidomycosis-
endemic areas in the United States (adapted from Kirkland TN, Fierer [2]). The figure on the right depicts New
York countywide distribution of 150 out of 161 patients in the discharge records (1992–1997); the highlighted
numbers show counties from which 45 of the 49 Coccidioides immitis cultures were referred to the state
mycology laboratory (1989–1997).28 28 28 28 28 Emerging Infectious Diseases Vol. 6, No. 1, January–February 2000
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exclusive reliance on hospital discharge sum-
mary data precluded detailed evaluation of
diagnostic criteria. Nevertheless, the average of
30 hospital discharges per year suggests that
coccidioidomycosis may be more common in New
York residents than previously recognized. The
largest number of positive cases was reported
from New York City, but the rate was not
increased, and cases were reported throughout
the state. Furthermore, while information on
travel history was limited, all 16 patients from
whom information was obtained had traveled to
disease-endemic areas before becoming ill.
Immunocompromised persons, infants, and
non-Caucasians are considered at increased risk
for coccidioidomycosis (1). The mean age of
patients in this series was 54 years, which is in
agreement with >40-year age-group most com-
monly diagnosed in disease-endemic areas (5,6).
As expected, a large proportion of patients had
other diagnoses consistent with underlying
immunosuppression, including a primary diag-
nosis of HIV in 20% and cancer in 10%. Overall,
75% were  55 years of age, had cancer, or were
HIV infected. The availability of C. immitis
cultures from only 10% of cases precluded any
definitive investigations of geographic areas in
which New Yorkers are at greater risk for
infection.
The discovery of recombination in clinical
isolates of C. immitis (14) has shown genetic
evidence of two sexually distinct taxa in this
pathogen, which was previously thought to
reproduce asexually (15). A corollary of these
investigations was the development of a
multilocus genotyping scheme for determining
the geographic origin of clinical isolates.
Although the discharge data available for this
study did not include travel information, we
were able to delineate Arizona isolates in a
subpopulation of our study for which cultures
and medical record travel data were available.
Thus, a patient’s travel history was correlated
with disease acquisition in a particular area by
independently demonstrating the geographic
pattern of the patient’s isolate in 13 (81%) of 16
patients evaluated. However, the typing scheme
could not determine the geographic origin of two
C. immitis isolates, which came from patients
thought to have traveled to both California and
Mexico. This discrepancy may have resulted
from the limited number of alleles used for
typing, incomplete travel histories, shortcom-
ings of the typing scheme for California isolates,
or the possibility that the two isolates belonged to
an outlier group of strains. Further testing is
needed on a larger set of isolates from different
geographic areas to evaluate this typing scheme.
Table 2. Correlation among clinical history, travel, and multilocus genotypes of Coccidioides immitis isolates from 16
patients, New York, 1994–1997
Isolate Clinical Treatmenta  Travel Multilocusc Typing
no. diagnosis outcome historyb genotype pattern
104-94      -      - AZ 01101 AZ
376-95 Pneumonia Itra/discharged AZ 11101 AZ
515-95 Immunocomp.d Amp B, Itra/died AZ/CA 11100 AZ
750-95      -      - AZ 11101 AZ
131-96 Pneumonia Flu/discharged AZ/TX 11100 AZ
229-96 Immunocomp. Amp B, Flu, Itra/died AZ 11101 AZ
366-96 Pneumonia No treatment/discharged AZ 11100 AZ
819-96 Immunocomp. Amp B, Itra/died AZ/CA 11100 AZ
269-97 Lung mass No treatment/discharged AZ 11100 AZ
371-97 Immunocomp. Amp B,Flu,Itra/discharged AZ 11100 AZ
474-97 Hydrocephalus Flu/discharged CA 11101 AZ
588-97 Pneumonia Amp B,Flu/discharged AZ 11101 AZ
639-97 Lung mass Thoracotomy/discharged CA/Mexico 11101 AZ
686-97      -      - Southwest 11100 AZ
779-97 Pneumonia Itra/discharged CA 11100 AZ
815-97 URIe Flu/discharged AZ/CA 11101 AZ
aAmp B, Amphotericin B; Flu, Fluconazole; Itra, Itraconazole.
bAZ, Arizona; CA, California; TX, Texas.
cThe presence of polymorphism was scored as 1 and its absence as 0; every isolate was assigned a five-numeral genotype.
dImmunocomp, immunocompromised.
eURI, upper respiratory infection.29 29 29 29 29 Vol. 6, No. 1, January–February 2000 Emerging Infectious Diseases
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As a result of this study, laboratories
participating in the New York State Clinical
Laboratory Evaluation Program (Mycology)
were alerted about the hazards posed by
C. immitis. A safe procedure for initial
examination of suspect cultures was recom-
mended. The laboratories were also provided
with guidelines for safe transport of C. immitis to
the state mycology laboratory for confirmation
and characterization.
The diagnosis and clinical management of
coccidioidomycosis in areas where the disease is
not endemic pose unique challenges. The clinical
symptoms of the disease mimic those of other
infectious diseases, which may result in
misdiagnosis and inappropriate treatment (1,16).
Additionally, C. immitis cultures could be easily
confused with a number of nonpathogenic fungi
by unsuspecting laboratory personnel, who are
at risk for infection. Increased awareness among
health-care providers is likely to help in the
timely diagnosis of coccidioidomycosis and the
prevention of associated illness and death among
patients in nondisease-endemic areas.
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